SABCS 2017

Questions About Treating Patients Using a CDK4/6 Inhibitor

Questions About Treating Patients Using a CDK4/6 Inhibitor

FEATURING:

Matthew P. Goetz, MD

CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer

CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer

FEATURING:

Matthew P. Goetz, MD

Breast Cancer, SABCS 2017

Hot Topics at SABCS 2017

Hot Topics at SABCS 2017

FEATURING:

Hope S. Rugo, MD

Breast Cancer, SABCS 2017

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer

FEATURING:

Hope S. Rugo, MD

Breast Cancer, SABCS 2017

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer

FEATURING:

Hope S. Rugo, MD

Breast Cancer, SABCS 2017

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?

FEATURING:

Hope S. Rugo, MD

Breast Cancer, SABCS 2017

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor

FEATURING:

Hope S. Rugo, MD

Breast Cancer, SABCS 2017

HER2-Positive Breast Cancer and CDK4/6 Inhibitors

HER2-Positive Breast Cancer and CDK4/6 Inhibitors

FEATURING:

Hope S. Rugo, MD

Breast Cancer, SABCS 2017

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to receive the free OPM print publications or weekly e‑Newsletter.

I'd like to receive:

OPM Print Edition

OPM Weekly e‑Newsletter

I have reviewed and consent to the terms of OPM's Privacy Policy, and OPM has my permission to retain my information in its database, and to forward pertinent communications to me.